KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Operating Income (2016 - 2025)

Historic Operating Income for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $8.0 billion.

  • Eli Lilly's Operating Income rose 8427.68% to $8.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 billion, marking a year-over-year increase of 8515.14%. This contributed to the annual value of $16.2 billion for FY2024, which is 5772.93% up from last year.
  • According to the latest figures from Q3 2025, Eli Lilly's Operating Income is $8.0 billion, which was up 8427.68% from $7.0 billion recorded in Q2 2025.
  • In the past 5 years, Eli Lilly's Operating Income ranged from a high of $8.0 billion in Q3 2025 and a low of $1.4 billion during Q2 2021
  • Moreover, its 5-year median value for Operating Income was $2.6 billion (2022), whereas its average is $3.3 billion.
  • Its Operating Income has fluctuated over the past 5 years, first tumbled by 3777.97% in 2023, then surged by 10106.13% in 2025.
  • Eli Lilly's Operating Income (Quarter) stood at $2.4 billion in 2021, then decreased by 11.82% to $2.1 billion in 2022, then skyrocketed by 44.97% to $3.0 billion in 2023, then skyrocketed by 77.32% to $5.3 billion in 2024, then skyrocketed by 50.27% to $8.0 billion in 2025.
  • Its Operating Income stands at $8.0 billion for Q3 2025, versus $7.0 billion for Q2 2025 and $5.3 billion for Q1 2025.